Combination of 5-flucytosine and Capsule-Binding Monoclonal Antibody in the Treatment of Murine Cryptococcus Neoformans Infections and in Vitro

J Antimicrob Chemother. 1996 Mar;37(3):617-22. doi: 10.1093/jac/37.3.617.

Abstract

The efficacy of combination therapy with 5-flucytosine and an IgG1 monoclonal antibody to Cryptococcus neoformans capsular glucuronoxylomannan was studied in vitro with J774. 16 murine macrophage-like cells and in vivo in murine cryptococcal infection. The combination of 5-flucytosine and IgG1 was more effective in reducing the numbers of C. neoformans colony-forming units in vitro and in vivo than either agent alone.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology*
  • Antifungal Agents / pharmacology*
  • Cryptococcosis / drug therapy
  • Cryptococcosis / therapy*
  • Cryptococcus neoformans / drug effects*
  • Cryptococcus neoformans / metabolism
  • Female
  • Flucytosine / pharmacology*
  • Immunoglobulin G / immunology
  • Macrophages / drug effects
  • Macrophages / microbiology
  • Mice
  • Mice, Inbred A
  • Microbial Sensitivity Tests
  • Phagocytosis / drug effects
  • Polysaccharides / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antifungal Agents
  • Immunoglobulin G
  • Polysaccharides
  • glucuronoxylomannan
  • Flucytosine